Eli Lilly and Company
LLY
Positions held
Your positionsLLY isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Eli Lilly's strong revenue growth of 47.7% year-over-year indicates a robust demand for its products, positioning it well against competitors in the pharmaceutical industry.
- In Q2 2026, Eli Lilly reported a revenue of $22.974 billion, a 16% increase from the previous quarter.
- The company's gross margin improved to 85.8% in Q2 2026, up from 81.9% in Q1 2026.
- Eli Lilly's high trailing P/E ratio of 38.85 suggests that the stock may be overvalued compared to its earnings, raising concerns for potential investors.
- The company's net income decreased to $7.095 billion in Q2 2026 from $7.396 billion in Q1 2026.
- Eli Lilly's operating margin, while strong, has shown fluctuations, dropping from 54.2% in Q2 2026 to 49.4% in Q1 2026.
Fundamentals
| Market cap | $1.04T | Enterprise value | $1.09T | Trailing P/E | 39.26 | Forward P/E | 24.55 |
| PEG | 1.15 | Price / book | 30.78 | Beta | 0.45 | Dividend yield | 0.59% |
| Revenue growth | 47.7% | Earnings growth | 26.2% | Gross margin | 83.4% | Operating margin | 54.2% |
| Profit margin | 33.5% | ROE | 102.3% | ROA | 20.4% | Debt / equity | 1.62 |
| Current ratio | 1.36 | Free cash flow | $11.07B | Analyst recommendation | buy | Mean target | $1,330.25 |
| 52w high | $1,292.65 | 52w low | $783.85 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $23.0B | $19.8B | $19.3B | $17.6B | $15.6B | — |
| Op margin | 54.2% | 49.4% | 46.6% | 47.6% | 45.1% | — |
| Net income | $7.1B | $7.4B | $6.6B | $5.6B | $5.7B | — |
| Gross margin | 85.8% | 81.9% | 82.5% | 82.9% | 84.3% | — |
| Gross profit | $19.7B | $16.2B | $15.9B | $14.6B | $13.1B | — |
| Operating income | $12.5B | $9.8B | $9.0B | $8.4B | $7.0B | — |
- Revenue +16% vs prior quarter ($23.0B vs $19.8B).
- Gross margin 85.8% (was 81.9% prior quarter).
- Operating margin expanded to 54.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $65.2B | $45.0B | $34.1B | $28.5B | — |
| Op margin | 45.6% | 37.8% | 30.3% | 29.0% | — |
| Net income | $20.6B | $10.6B | $5.2B | $6.2B | — |
| Gross margin | 83.0% | 81.3% | 79.2% | 76.8% | — |
| Gross profit | $54.1B | $36.6B | $27.0B | $21.9B | — |
| Operating income | $29.7B | $17.0B | $10.3B | $8.3B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Record Highs Beckon for Big Caps as Small Caps Lag and Deal Flow Builds
2026-10-09 · Eli Lilly (LLY) As Zepbound And Retatrutide Updates Test Whether More Upside Is Priced In
2026-10-09 · BofA Securities Adjusts Eli Lilly Price Target to $1,341 From $1,344, Maintains Buy Rating
2026-10-09 · Eli Lilly (LLY) Posted 48% Revenue Growth. Why Does the Stock Trade Below Its Average Multiple?
2026-10-09 · Eli Lilly’s Biggest Shareholder Just Filed to Sell $347 Million of Stock
2026-10-09 · Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks
2026-10-09 · Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
2026-10-09 · TRex Bio IPO raises $116.7 million, prices at bottom of range
2026-10-09 · Lilly Says Taltz-Zepbound Combination Delivers Broader Biomarker Changes in Adults With Psoriasis, Obesity
2026-10-09 · UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.
2026-10-09 · Should You Be Worried About Pfizer Stock?
Price (daily)
Full chart · RSI · MACD · patterns